This content is from: Patents
“Far-reaching impacts” of Federal Circuit ruling on ANDA personal jurisdiction
The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics
Get Free Access to read more …
To read the full article, activate your free trial.
Get Free Access- Unlimited articles for one week
- No commitments; no payment details required
- Featuring IP strategy, copyright, patents, trademark and more!
Are you a Managing IP subscriber? Simply login here.